A Phase 4 interventional study of Intravenous iron sucrose and Lactoferrin in Iron Deficiency Anemia, sponsored by Ain Shams University. Not yet recruiting. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-07-19.
Sponsored by Ain Shams University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing iron sucrose in Anemia, Iron-Deficiency — 4 open to participants now, 5 under way, none of them phase 3. iron sucrose · Anemia, Iron-Deficiency.
Among the 17 studies testing iron sucrose in Anemia, Iron-Deficiency, this one is the 6th largest by planned enrollment, is one of 2 that started in 2023, is one of 7 in phase 4, and was the 12th registered.
602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.
Browse Anemia, Iron-Deficiency studies →4 of the 17 studies testing iron sucrose in Anemia, Iron-Deficiency are open now, in 2 countries. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–50 · Women only
Kharadar General Hospital · Sites in Pakistan
Ages 12 mo–59 mo
Hawler Medical University
Ages 18–45 · Women only
By country, each count listing its studies:
iron sucrose: first FDA approval 2000 (VENOFER). What it is approved for, and how studies give it, is on its page →
Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 7
First in 2004; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 100 is close to the median of 100 across 461 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 74 across the 17 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
10 studies in Anemia, Iron-Deficiency by Ain Shams University: 2 open now, 2 under way, none of them phase 3. Of 7 finished, 0 (0%) have results posted.
Among the 10 studies in Anemia, Iron-Deficiency by Ain Shams University, this one is one of 2 that started in 2023, is one of 5 in phase 4, and was the 8th registered.
Ain Shams University’s Anemia, Iron-Deficiency studies by the year they started, since 2013.
3 of the studies testing iron sucrose in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07706582Beni-Suef UniversityManagement of Iron Deficiency Anemia in Hemodialysis Patients | 2026-12 |
| NCT07657091Kharadar General HospitalCOMPARISON OF EFFICACY OF ORAL VS IV IRON THERAPY IN CHILDREN AGED 12-59 MONTHS, WITH IRON DEFICIENCY ANEMIA | 2027-06-30 |
| NCT06061393Western Galilee Hospital-NahariyaComparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing iron sucrose in Anemia, Iron-Deficiency, from their registry updates:
Among Ain Shams University’s 10 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Iron deficiency is the most common nutritional deficiency and the most common cause of anemia. Anemia has a significant impact on the health of the fetus as well as that of the mother. It impairs the oxygen delivery through the placenta to the fetus and interferes with the normal intrauterine growth, leading to fetal loss and perinatal deaths. Anemia is associated with increased preterm labor (28.2%), preeclampsia (31.2%), and maternal sepsis.
The study aims to compare the effect of Lactoferrin versus intravenous iron sucrose for the treatment of iron deficiency anemia during pregnancy.
Iron deficiency is the most common nutritional deficiency and the most common cause of anemia. Anemia has a significant impact on the health of the fetus as well as that of the mother. It impairs the oxygen delivery through the placenta to the fetus and interferes with the normal intrauterine growth, leading to fetal loss and perinatal deaths. Anemia is associated with increased preterm labor (28.2%), preeclampsia (31.2%), and maternal sepsis.
The study aims to compare the effect of Lactoferrin versus intravenous iron sucrose for the treatment of iron deficiency anemia during pregnancy.
The study will include 100 pregnant women with moderate iron deficiency anemia. They will assigned randomly in to 2 groups. Each group will contain 50 patients.
The first group will receive intravenous iron sucrose (sacrofer 100mg/5ml)as 200 mg elemental iron in 100 ml 0.9 NaCl over 20-30 minutes up to the total dose -Total dose will be calculated from this equation=weight(kg)x(target Hb in g/dl-actual Hb in g/dl)x2.4+500 rounded up to the nearest multiple of 100 mg The second group will receive lactoferrin 100 mg twice daily orally before breakfast and before dinner (pravotin 100 mg sachets will be dissolved in ¼ glass of water). Patients will be advised to avoid coffee, milk products and antacid before and after the dose of lactoferrin.
All women in the study will be submitted to:
Complete History Taking Including:
Investigations:
Kidney function tests and liver function tests. 2. Follow up assessment:
In between visits, patients will be contacted via phone for monitoring of any side effects.
Inclusion Criteria:
Exclusion Criteria:-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 pregnant women will receive 200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose -The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg
Drug: Intravenous iron sucrose
50 pregnant women will receive lactoferrin 100 twice daily orally .
Drug: Lactoferrin
200 mg elemental iron in 100 ml 0.9 NaCl intravenous over 20 -30 minutes daily up to the total dose) o The dose of the total iron sucrose to be administrated was calculated from the following formula: Total dose required = weight (kg) x (target Hb in g\\dL - actual Hb in g\\dL) x 2.4 + 500 mg rounded up to the nearest multiple of 100 mg
Also known as: Intravenous iron sucrose(Sacrofer 100mg/5ml) was manufactured by Amoun company for pharmaceutical and chemical industry ,Egypt.
100 mg twice daily orally before breakfast and dinner
Also known as: lactoferrin 100 mg (Pravotin100 mg sachet)was manufactured by Hygint company for pharmaceutical and chemical industry,Egypt. Egypt) twice daily orally .
evaluate the effect of oral lactoferrin as compared to intravenous iron sucrose on the serum level of ferritin
estimation serum ferritin level
Time frame: 4 weeks
evaluate the effect of oral lactoferrin as compared to intravenous iron sucrose on the serum level of hemoglobin
estimation hemoglobin level
Time frame: 4 weeks
evaluation of lactoferrin side effect
assessment of the incidence rate of nausea, vomiting and GIT upset
Time frame: 4 weeks
the incidence rate of constipation
Time frame: 4 weeks
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jul 2023; primary completion for Jan 2024, 5 months later.
Of 43 non-industry phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's planned 5 months is below that.
Counting every sponsor, half of 51 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iron sucrose · Lactoferrin